UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4485-4491

2010

Volltextzugriff (PDF)

Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

The oncologist (Dayton, Ohio), 2016-10, Vol.21 (10), p.1218-1229

2016

Volltextzugriff (PDF)

Long‐Term Outcome of Ustekinumab Therapy for Behçet's Disease

Arthritis & rheumatology (Hoboken, N.J.), 2019-10, Vol.71 (10), p.1727-1732

2019

Volltextzugriff (PDF)

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

European journal of cancer (1990), 2017-05, Vol.76, p.36-44

2017

Volltextzugriff (PDF)

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders

Translational psychiatry, 2017-03, Vol.7 (3), p.e1056-e1056

2017

Volltextzugriff (PDF)

Vismodegib: A Review in Advanced Basal Cell Carcinoma

Drugs (New York, N.Y.), 2018-07, Vol.78 (11), p.1145-1156

2018

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-01, Vol.32 (2), p.76-82

2014

Volltextzugriff (PDF)

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

The lancet oncology, 2017-05, Vol.18 (5), p.672-681

2017

Volltextzugriff (PDF)

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

Digestive diseases and sciences, 2016-10, Vol.61 (10), p.3072-3083

2016

Volltextzugriff (PDF)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

BMC cancer, 2022-03, Vol.22 (1), p.304-304, Article 304

2022

Volltextzugriff (PDF)

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

The lancet oncology, 2012-04, Vol.13 (4), p.375-384

2012

Volltextzugriff (PDF)

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2015-12, Vol.107 (12), p.djv258-djv258

2015

Volltextzugriff (PDF)

Relevance of CYP3A420, UGT1A137 and UGT1A128 variants in irinotecan‐induced severe toxicity

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1389-1392

2018

Volltextzugriff (PDF)

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2005-01, Vol.16 (1), p.90-96

2005

Volltextzugriff (PDF)

FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies

European journal of cancer (1990), 2022-05, Vol.167, p.23-31

2022

Volltextzugriff (PDF)

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study

Clinical colorectal cancer, 2023-03, Vol.22 (1), p.59-66

2023

Volltextzugriff (PDF)

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

Diabetes, obesity & metabolism, 2012-12, Vol.14 (12), p.1061-1072

2012

Volltextzugriff (PDF)

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

European journal of cancer (1990), 2013-12, Vol.49 (18), p.3780-3787

2013

Volltextzugriff (PDF)

Docetaxel-related side effects and their management

European Journal of Oncology Nursing, 2009-02, Vol.13 (1), p.49-59

2009

Volltextzugriff (PDF)

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy

Anticancer research, 2018-06, Vol.38 (6), p.3689-3697

2018

Volltextzugriff (PDF)

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

British journal of haematology, 2016-06, Vol.173 (5), p.722-730

2016

Volltextzugriff (PDF)

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

British journal of haematology, 2019-12, Vol.187 (5), p.615-626

2019

Volltextzugriff (PDF)

1 – 25 von 318

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(262)
Mit Volltextzugriff
(187)

Publikationsform

Artikel
(318)

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(308)
Asthenia - Chemically Induced
(248)
Female
(218)
Science & Technology
(205)
Life Sciences & Biomedicine
(201)
Male
(200)
Middle Aged
(188)
Adult
(165)
Aged
(148)
Oncology
(101)
Treatment Outcome
(81)
Biological And Medical Sciences
(74)
Medical Sciences
(74)
Pharmacology. Drug Treatments
(57)
Drug Administration Schedule
(52)
Asthenia
(50)
Pharmacology & Pharmacy
(47)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(45)
Neutropenia - Chemically Induced
(42)
Nausea - Chemically Induced
(41)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Long‐Term Outcome of Ustekinumab Therapy for Behçet's Disease

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders

Vismodegib: A Review in Advanced Basal Cell Carcinoma

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

Relevance of CYP3A420, UGT1A137 and UGT1A128 variants in irinotecan‐induced severe toxicity

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies

Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

Docetaxel-related side effects and their management

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy

A phase II, single‐arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B‐cell lymphoma

Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukaemia in chronic phase: a prospective observational study in daily clinical practice

Suchergebnisse filtern